Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Profit After Tax (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Profit After Tax for 16 consecutive years, with -$7.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax fell 404.78% to -$7.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was -$17.3 million, a 176.26% decrease, with the full-year FY2025 number at -$3.0 million, down 987.55% from a year prior.
  • Profit After Tax was -$7.4 million for Q4 2025 at PharmaCyte Biotech, up from -$8.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $23.4 million in Q3 2024 to a low of -$8.4 million in Q3 2025.
  • A 5-year average of -$264105.8 and a median of -$886396.0 in 2021 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: surged 1165.95% in 2024, then crashed 404.78% in 2025.
  • PharmaCyte Biotech's Profit After Tax stood at -$979746.0 in 2021, then tumbled by 91.94% to -$1.9 million in 2022, then soared by 248.36% to $2.8 million in 2023, then plummeted by 152.67% to -$1.5 million in 2024, then plummeted by 404.78% to -$7.4 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Profit After Tax are -$7.4 million (Q4 2025), -$8.4 million (Q3 2025), and -$812788.0 (Q2 2025).